ClinicalTrials.gg
CompletedNCT05857267Updated Nov 6, 2024

Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

A Phase 4 interventional study of Dorzolamide / Timolol Ophthalmic Solution and dorzolamide/timolol in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Laboratorios Poen. Completed at 6 sites in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Laboratorios Poen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing dorzolamide in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. dorzolamide · Glaucoma, Open-Angle.

Enrollment
7th of 14
84 · median 74
Started
2023
the only one that year
Phase 4
12 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Laboratorios Poen

Among the 14 studies testing dorzolamide in Glaucoma, Open-Angle, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 12 in phase 4, and was the 13th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 14 studies testing dorzolamide in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About dorzolamide

dorzolamide: first FDA approval 1994 (TRUSOPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing dorzolamide in Glaucoma, Open-Angle as a file.
02

Study summary

The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older than 18 years old
  • Patients with POAG and OH
  • PIO \< 20 mmHg
  • Under treatment with Dorzolamide + Timolol BAK preserved at least 6 month after
  • OSDI > 13 \& one of these ocular signs (BUT \<6sec or Schirmer test \< 5 mm/5min or corneal staining positive)
  • Corneal thickness between 520-580 um.

Exclusion criteria

Exclusion Criteria:

  • Patient with severe respiratory diseases (asthma, and other bronchospactic diseases).
  • Patient with cardiovascular diseases (Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock).
  • Severe renal impairment ( \<30 mL/min)
  • Progressive diseases of the retina other than glaucoma
  • Inflammation and/or infecctions active
  • Ocular surface syndrome other than Ocular Surface disease
  • Eyelid disorder
  • Systemic adminsitration of Betablockers or carbonic anhydrase inhibitors
  • Patient that requires another antigluacomatous eye drop other than fixed combination of Dorzolamide/Timolol
  • Patients who use regularly lubricant eye drops
  • Patient who use regularly contact lenses
  • Patient with autoinmune diseases
  • Patients who underwent kerato-refractive laser procedures, cornea or corneal surface surgery, including, but not limited to, LASIK and PRK, within 6 months prior to the baseline visit.
  • Patients who have undergone a laser procedure or intraocular surgery or extraocular in either eye within 6 months prior to the baseline visit.
  • Patients with severe central visual field loss in either eye based onclinical judgment of the investigator. For the Humphrey and Octopus perimeters, the severe loss The visual field is defined as a sensitivity less than or equal to 10 dB in at least two(2) of the four (4) visual field test points closest to the fixation point
  • Patients with known to any of the components of bothdrugs under study.
  • Pregnant or lactating women.
  • Women of childbearing age who are not using a method.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Dorzolamide+Timolol PF

    Glaucotensil TD LC, Laboratorios Poen

    Drug: Dorzolamide / Timolol Ophthalmic Solution

  • Experimental
    Dorzolamide + Timolol BAK

    Glaucotensil TD, Laboratorios Poen

    Drug: dorzolamide/timolol

Interventions

  • DrugDorzolamide / Timolol Ophthalmic Solution

    Drug pages: Dorzolamide · Timolol

    Dorzolamide-timolol fixed combination in a preservative-free multidose device

    Also known as: Glaucotensil TD LC

  • Drugdorzolamide/timolol

    Drug pages: Dorzolamide · Timolol

    Dorzolamide-timolol BAK-preserved fixed combination

    Also known as: Glaucotensil TD

06

What researchers measure

Primary outcomes

  1. Ocular Surface Disease Symptoms

    OSDI questtionarie

    Time frame: Change from baseline in OSDI score at 24 weeks

Secondary outcomes

  1. Intraocular preassure

    Intraocular preassure (PIO) by GAT

    Time frame: Change from baseline in PIO (mmHg) at 24 weeks

  2. Break-up Time

    Break-up Time (BUT)

    Time frame: Change from baseline BUT (seconds) at 24 weeks

  3. SCHIRMER-ITEST

    Schirmer test without anesthesia

    Time frame: Change from baseline Shirmer test (mm) at 24 weeks

  4. Conjunctival Hyperemia

    Conjunctival Hyperemia

    Time frame: Change from baseline in porcentaje of patients with conjunctival hyperemia at 24 weeks

  5. Satisfaction questionnaire

    Satisfaction questionnaire

    Time frame: Change from baseline of patient satisfaction at 24 weeks using a 5-point likert scale

  6. Best corrected visual acuity

    snellen scale 20/20

    Time frame: Change from baseline visual acuity at 24 weeks

  7. Treatment preference

    Treatment preference

    Time frame: Treatment preference with respect previous treatment at Week 24

Other outcomes

  1. Superficial corneal epithelium density

    Superficial corneal epithelium density analyzed by confocal microscopy expresed by cells /mm2

    Time frame: Change from baseline superficial corneal epithelium density at 48 weeks

  2. Basal corneal epithelium density

    Basal corneal epithelium density analyzed by confocal microscopy expresed by cells /mm2

    Time frame: Change from baseline basal corneal epithelium density at 48 weeks

  3. Corneal Estroma reflectivity

    Corneal Estroma reflectivity analyzed by confocal microscopy expresed by 5-point scale of grade

    Time frame: Change from baseline in the grade of corneal estroma reflectivity at 48 weeks specify by 4 grade scale reported by Martone et al. .

  4. Corneal nerve density

    Corneal nerve density analyzed by confocal microscopy expresed by cells /mm2

    Time frame: Change from baseline corneal nerve density at 48 weeks

  5. Neuroma density

    Neuroma density analyzed by confocal microscopy expresed by neuromas/mm2

    Time frame: Change from baseline neuroma density at 48 weeks

  6. Dendrite density

    Dendrite density analyzed by confocal microscopy expresed by dendrites/mm2

    Time frame: Change from baseline dendrite density at 48 weeks

  7. Corneal nerve tortuosity

    Corneal nerve tortuosity analyzed by confocal microscopy expresed by 5-point scale of grade

    Time frame: Change from baseline in the grade of corneal nerve tortousity at 48 weeksusing a 5 point scale reported by Oliviera-Soto et al.

  8. Endothelial cell density

    endothelial cell density analyzed by confocal microscopy expresed by cells/mm2

    Time frame: Change from baseline endothelial cell count at 48 weeks

  9. Conjuctival epithelium density

    Conjuntival epithelium density analyzed by confocal microscopy expresed by cells/mm2

    Time frame: Change from baseline conjuctival epithelium density at 48 weeks

  10. Goblett cell density

    Goblett cell density nalyzed by confocal microscopy expresed by cells/mm2

    Time frame: Change from baseline goblett cell density at 48 weeks

  11. Inflamatory infiltrates

    Description of presence or absence of inflamtory cells on conjuntiva

    Time frame: Change from baseline in inflamatory infiltrates at 48 weeks

07

Study locations

6 sites
  • Clínica de Ojos Dr. Nano
    Olivos, Buenos Aires B1636CSS, Argentina
  • Consultorio Dr. Peyret
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aires C1007ABK, Argentina
  • Gonella Oftalmólogos
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aires C1122AAK, Argentina
  • Centro Diagnóstico Dr. Gentile
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aires C1425AYA, Argentina
  • Centro oftalmológico Dr. Casiraghi & asociados
    Ciudad Autónoma de Buenos Aire, Ciudad Autónoma De Buenos Aires C1124, Argentina
  • Consultorios de Oftalmología
    Ciudad autónoma de Buenos Aires, C1425FAB, Argentina
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2024, 19 months.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
May 12, 2023
StartActual
Mar 7, 2023
Primary completionActual
Nov 4, 2024
CompletionActual
Nov 4, 2024
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05857267
Lead sponsor
Laboratorios Poen
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Mar 7, 2023
Primary completion
Nov 4, 2024
Completion
Nov 4, 2024
Last update
Nov 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dorzolamide · Timolol

Start the discussion